QED Therapeutics
0 followers
QED Therapeutics, a subsidiary of BridgeBio Pharma, is a biotechnology company focused on precision medicine for FGFR-driven disorders. QED is also evaluating infigratinib in preclinical studies for the treatment of achondroplasia. They plan to develop infigratinib in additional FGFR-driven tumor ty... Read more
Org chart
Matt Outten
Chief Executive Officer
Matt Outten
Collapse
Rick Panicucci
SVP of CMC
Daniela Rogoff, MD, PhD.
Sr Vice President of Clinical Development
Dave Martin
Vice President Nonclinical and Clinical Pharmacology
David van Veenhuyzen
Vice President Clinical Development
Deborah Mortensen
Director, Medical Writing
Mike Monteith
Senior Vice President, Pharmaceutical Development, QED Therapeutics
Vanessa Solis
Senior Executive Administrator to COO
Joyce Velez
Clinical Data Manager
Ariana Salvatici
Associate Medical Director
